Clinical Trial Update: A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating liposomal irinotecan plus 5-FU/leucovorin hepatic arterial infusion with lenvatinib and a PD-1 inhibitor in advanced intrahepatic chola…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Lenvatinib (lenvatinib)
• Leucovorin (folinic acid)
• Liposomal irinotecan (liposomal irinotecan)
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING